Navigation Links
Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
Date:5/12/2008

MONTVALE, N.J., May 12 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) is increasing the Company's commercial focus with the appointment of David C. Tantillo as Senior Director, Marketing and Sales, a newly created position. Beginning today, Mr. Tantillo will be responsible for planning and implementing commercialization of the Company's haptoglobin diagnostic test. Synvista expects commercial launch of this product in mid- 2009.

Mr. Tantillo brings to Synvista nearly 20 years of broad-based industry experience, having successfully directed programs in diabetes, oncology, infectious disease, pain, inflammation and other therapeutic areas. His work has included diagnostics, pharmaceuticals, and medical devices, as well as health and disease management services and managed care initiatives. His experience also includes a combination diagnostic, drug and drug delivery device. He has overseen marketing programs for commercial products, as well as those in early- and late-stage clinical development. He also has been involved in several marketing and development partnerships, as well as with new business acquisitions.

"David has a strong track record of success, and we are delighted to welcome him to the Synvista team to initiate our first commercialization program for our haptoglobin diagnostic," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista Therapeutics. "We look forward to working with David to usher in a new era for Synvista, relying heavily on his extensive experience in bringing products to market, specifically with testing products and in the diabetes arena."

Prior to joining Synvista, Mr. Tantillo was Director Strategic Marketing at Alpharma Pharmaceuticals. Fro
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
2. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to be Featured on Wallst.net
5. Synvista Therapeutics to Present at the BIO InvestorForum 2007
6. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
7. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
8. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
9. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
10. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
11. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... PROVO, Utah , April 21, 2015  Tute Genomics, ... the hiring of Josh Forsythe as VP of ... that has witnessed a significant expansion in its commercial operations ... " Josh Forsythe is a ... Robison , MD MBA, CEO of Tute Genomics. "Josh,s vast ...
(Date:4/21/2015)... RESEARCH TRIANGLE PARK, N.C. , April 21, 2015 ... announced today that it will release its first quarter ... 28, 2015. United Therapeutics will host a ... a.m. Eastern Time.  The teleconference is accessible by dialing ... the teleconference will be available for one week and ...
(Date:4/21/2015)... Whether it’s used for troubleshooting in a ... a Kessler CineDrive in a cinematic studio setting, ... TS3-H is designed to help any shooter create vivid ... sensor, the TS5-H offers the same convenient touchscreen controls and ... , According to Tom Boldt for Fastec, “We believe that ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 PMG ... its 12th clinical research site: PMG Research of Christie ... operation of the clinical research department at Christie ... the Southeast to a second region within the United ... physician practice enhances PMG’s access to an additional 80,000 ...
Breaking Biology Technology:Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 2Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 3PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 2PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 3
... , , MISSISSAUGA, ON, Nov. 23 /PRNewswire-FirstCall/ ... TSX: YM), a life sciences product development company that ... products at various stages of development, today reported that ... trial evaluating CYT387, a potent, orally-administered JAK1/JAK2 inhibitor. The ...
... , , SEATTLE, Nov. ... Bruce L.A. Carter has joined IDC as Executive Chairman. ... management. He was the former Chief Executive Officer at ... Nordisk, Copenhagen, Denmark. , (Photo: http://www.newscom.com/cgi-bin/prnh/20091123/SF15228 ) ...
... , REDWOOD CITY, Calif., Nov. ... therapeutic products for the treatment of chronic respiratory diseases, ... company,s Board of Directors. Mr. Rosen has 25 years ... key roles at Gilead Sciences and ALZA Corporation. His ...
Cached Biology Technology:YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 5Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2Pearl Therapeutics Appoints Howie Rosen to Board of Directors 2
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... in the brain may unlock the mystery behind the ... issue of Cell. Hibernation allows animals from bears to ... the harshest of winter conditions. , If the findings ... first essential brain signal governing the seasonal adaptation, according ...
... amino acid supplement L-arginine following a heart attack does ... be associated with an increased risk of death, according ... JAMA. , L-arginine is a widely available dietary supplement ... hypertension, angina, heart failure and sexual dysfunction, according to ...
... "biobullet" that could help control an invasive mollusk that ... water pipes, virtually wiping out some native mussels species ... new microcapsules, which contain toxins that dissolve within a ... way of eliminating one of the world's "most important ...
Cached Biology News:Possible brain hormone may unlock mystery of hibernation 2Possible brain hormone may unlock mystery of hibernation 3Use of amino acid supplement following a heart attack provides no benefit, may be harmful 2'Biobullets' fight harmful mussels 2
...
...
...
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
Biology Products: